NCT04465396 - A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

August 20, 2021

Study Completion Date

August 20, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

Teduglutide

Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.

DEVICE

Syringe Injection

Teduglutide was administered using syringe.

DEVICE

Pen injector

Teduglutide was administered using pen injector.

Trial Locations (1)

85283

Celerion, Phoenix